Drugs / MRZ
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00461045 | Mar 2007 → Sep 2014 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRZ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00461045 ↗ |
| Action | Inhibit | “MRZ inhibits the 3 proteolytic activities of the 20S proteasome” PMID 27009059 ↗ Mar 2016 |